Navigation Links
Genomic Health to Present at the JMP Securities Healthcare Conference
Date:9/21/2011

REDWOOD CITY, Calif., Sept. 21, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Dean Schorno, Genomic Health's Chief Financial Officer, will present at the JMP Securities Healthcare Conference in New York City on Tuesday, September 27, 2011 at 3:00 p.m. Eastern Time (ET).  

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads.  An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.  Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer.  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease.  As of June 30, 2011, more than 10,000 physicians in over 60 countries had ordered more than 200,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional stages of breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests;  the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly  Report  on Form 10-Q  for the period ended June 30, 2011. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/12/2017)... , May 12, 2017  The China and ... washing technology that consumes less water, energy and detergent, and features ... first product LaughingU, a shoebox-sized washing machine that washes and sanitizes ... ... Product, LaughingU, is compact, and does not require an external water ...
(Date:5/10/2017)... WASHINGTON , May 10, 2017  The ... doctors or employees of sleep therapy clinics to ... a sleep therapy clinic is involved in a ... as interested in hearing from an employee of ... involved in a kickback scheme to provide medical practice ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... New ... the SPEED System™ Orthodontics, with or without a referral, from the multi-specialty Dr. ... Segundo, CA, who is skilled in providing patients with the custom, convenient and ...
(Date:5/23/2017)... ... May 23, 2017 , ... Patients in need of ... Angela Cotey’s practice to schedule an appointment, with or without a referral. Dr. Cotey ... pulpotomy treatments to pediatric patients as a healthy alternative to a tooth extraction. , ...
(Date:5/22/2017)... ... 2017 , ... Patients who avoid necessary dental and endodontic treatments because of ... NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three different ... sedation methods may be recommended based on the severity of the anxiety experienced by ...
(Date:5/22/2017)... ... ... Today, Our Urgent Care celebrates the grand opening of its newest urgent ... opening over a month ago, Our Urgent Care Washington has enjoyed serving Franklin County ... Care walk-in clinic is located at 3195 Phoenix Center Dr., Washington, MO 63090 in ...
(Date:5/22/2017)... ... 22, 2017 , ... “Homeostasis: The Journey of a Manic-Depressive” tells the story ... Donald Rodriguez takes readers on a rollercoaster ride that includes a midnight trek to ... to a dark place where Donald considers suicide. Readers learn how Donald finally ...
Breaking Medicine News(10 mins):